Skip to main content
Premium Trial:

Request an Annual Quote

Chicago Trust Awards $25M-$50M for Systems Bio, Proteomics Research at Chicago Biomedical Consortium

NEW YORK, Feb. 9 (GenomeWeb News) - The Searle Funds at the Chicago Community Trust has awarded $5 million to the Chicago Biomedical Consortium and plans to continue annual donations in that amount for at least five years, said the consortium today.


The grant is designed to "support and stimulate innovative multi-institutional collaborations in research and education," said the consortium, which focuses on systems biology and proteomics.


The funds will be used to recruit faculty members in the areas of proteomics and bioinformatics as well as to provide grants, develop infrastructure and educational programs, and foster relationships with Chicago industry. 


Under the agreement, the program will be reviewed in its fourth year and possibly renewed for an additional five years.


The CBC was established in 2002 by scientists at Northwestern University, University of Chicago, and the University of Illinois at Chicago. As GenomeWeb News reported last January, the consortium received $2 million from the SearleTrusts to acquire a Fourier transform mass spectrometer.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.